At the height of his career as a NASA astronaut, Rich Clifford went in for a routine physical with his flight surgeon and came out with a life-changing diagnosis: Parkinson’s disease (PD). With no prior knowledge of the condition and only a single, minor symptom—some limpness in his right arm—the diagnosis seemed incomprehensible to Rich, yet threatened to bring his professional life to a screeching halt.

Rich was suddenly facing the harsh realities of PD, a progressive neurodegenerative disease that results in the breakdown of dopamine-producing cells in the brain, leading to impaired movement, tremors, apathy and depression, among other symptoms. The condition is the fastest-growing neurodegenerative disorder in the U.S., with approximately 60,000 Americans diagnosed each year, according to the Parkinson’s Foundation. Nearly one million will be living with PD in the U.S. by 2020, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and Amyotrophic Lateral Sclerosis (ALS).

There is no diagnostic test for PD and no way to slow or stop its progression. From the time of Rich’s diagnosis 24 years ago through today, treatments can only help mitigate symptoms.

Dr. Doug Williamson, chief medical officer and vice president of U.S. medical at Lundbeck, is hoping to change that reality. A psychiatrist by training, Dr. Williamson entered the biopharmaceutical industry to study treatments for diseases of the brain, such as PD and Alzheimer’s, with the understanding that new medicines could impact lives on a scale far greater than one-on-one treatment.

Historically, Dr. Williamson’s area of research has posed significant challenges. The brain is a notoriously difficult organ to study, in part due to the blood-brain barrier, which shields the brain from foreign substances—including medicines that could provide effective treatment. Additionally, many diseases that afflict the brain can only be diagnosed by ruling out all other options. This includes Parkinson’s disease; Rich only received his diagnosis after testing negative for everything else.

Yet, due to advances in our understanding of genetics and disease pathology, the future looks bright for PD research, says Dr. Williamson.

“I feel as if we’re on the verge of making a major leap forward in our understanding of Parkinson’s disease and our ability to treat it,” he says. “Already, we’ve made great strides in discovering better ways to manage the breakdown in motor systems. We also know more about the mechanisms behind other symptoms, which is helping develop treatments for those as well.”
CCTT Thumbnail

PhRMA COVID-19 Treatment Progress

America’s biopharmaceutical companies are coming together to achieve one common goal: ending COVID-19. Our shared heritage of discovery and research allows us to respond to the coronavirus swiftly, with active trials for both treatments and vaccines already underway.

Rich, who never felt his PD diagnosis should place limits on what he could achieve, maintains a similar sense of hope. For more than two decades, he has lived a full life as a Parkinson’s patient, including an additional trip to space, which took place under the guidance of his physicians at NASA after his diagnosis. It’s the same sense of optimism that drives Dr. Williamson, and the thousands of researchers like him, forward every day.

“I would tell patients who have been newly diagnosed with Parkinson’s that they shouldn’t lose hope,” says Dr. Williamson. “We go to work every day thinking about them. We’re close to finding a breakthrough in areas like Parkinson’s, and we won’t quit until we do.”

Ready to Get Involved?

Or sign up to stay informed: